1. Analyst: Ryan Youngstrand Saturday, September 5, 2009

2.  Stock Price  $51.16  52-week range  $35.89-54.95  Beta  0.14  EPS (TTM)  $1.10

3.  Sector: Healthcare  Industry : Drug Manufacturers – Other  “The company was founded in 1901 and is headquartered in Petach Tikva, Israel” (Yahoo! Finance).  “…engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide” (Yahoo! Finance).

4.  “…principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson’s disease” (Yahoo! Finance).  “…also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler, and Cyclohaler, a single dose dry powder device” (Yahoo! Finance).  “It has a collaboration agreement with Optimata Ltd. To develop solid tumor cancer drugs; a strategic alliance with Kowa Company, Ltd. to establish a generic pharmaceutical company in Japan; and a strategic partnership with the Lonza Group in a joint venture to develop, manufacture, and market a portfolio of biogenerics” (Yahoo! Finance).

5.  Strengths:  Good Potential for Growth  International Company  Products Necessities  Sheltered from the economic condition.  Weaknesses:  Since it is an international company, international risk exists (exchange rates, international and trade laws, etc.).

6.  Opportunities:  The growing opportunity for biogeneric products and services.  Threats  Competition  International Risk  Recalls

7. RatioTEVAIndustryOutperform/ Underperform Current Ratio1.52Vs.3.37Underperform Interest Coverage-Vs.0.67- TAT0.43Vs.0.04Outperform Receivables Turnover 3.00Vs.0.32Outperform Return on Assets3.30Vs.0.61Outperform

8. RatioTEVAIndustryOutperform/ Underperform Return on Equity5.6Vs.1.15Outperform Net Profit Margin7.73Vs.0.76Outperform EPS (TTM) vs. TTM 1 Yr. Ago -54.54Vs.-- Projected 5-year EPS Growth -7.69Vs.3.88Underperform Sales – 5 Yr. Growth Rate 27.6Vs.12.42Outperform

9. RatioTEVAIndustryOutperform/ Underperform PEG1.91Vs.24.5Outperform P/E52.68Vs.1.47Outperform Dividend Yield1.22Vs.0.06Outperform

10. RatioTTM20042005200620072008 Current Ratio 1.351.912.441.881.841.35 Equity Multiplier 2.021.791.721.841.712.02 Rec. Turnover 2.73.02.63.32.92.7 TAT0.390.620.520.540.430.39 ROA (%)2.264.2710.713.548.902.26 ROE (%)4.237.6518.766.3515.704.23 Net Profit Margin (%) 5.736.9120.426.4920.755.73 Rev. Growth (%) 10.646.59.460.111.917.8 EPS Growth (%) -(58.2)218.0(56.6)244.9(67.2)

11.  TTM = 635.0  2008 = 635.0  2007 = 1,952.0  2006 = 546.0  2005 = 1,072.3  2004 = 331.8  2003 = 691.0  2002 = 410.3  2001 = 278.2  2000 = 148.4  1999 = 117.8

12.  EPS from Net Income  TTM = 0.78  2008 = 0.78  2007 = 2.38  2006 = 0.69  2005 = 1.59  2004 = 0.50  2003 = 1.20  2002 = 0.76  2001 = 0.51  2000 = 0.29  1999 = 0.24

13.  PEG (5 Yr. Expected) = 0.88  Market Cap = 44.71B  PEGY = -8.14  EPS Growth = -7.69  Current Ratio = 1.52  P/E = 54.6  ROE = 4.23%  ROA = 2.26%

14. 2-YEAR STOCK CHART

15. COMPARISON WITH COMPETITORS AND S&P 500

16.  HOLD (Growth, Large Cap Stock)